Detalhe da pesquisa
1.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Clin Infect Dis
; 78(6): 1462-1472, 2024 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305378
2.
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Blood
; 133(10): 1011-1019, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30530801
3.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(1): 43-56, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30522969
4.
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Biol Blood Marrow Transplant
; 25(10): 2002-2007, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31260802
5.
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Br J Haematol
; 182(4): 504-512, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29873072
6.
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Br J Haematol
; 180(6): 821-830, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435979
7.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
N Engl J Med
; 373(25): 2425-37, 2015 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26639149
8.
Ibrutinib in previously treated Waldenström's macroglobulinemia.
N Engl J Med
; 372(15): 1430-40, 2015 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25853747
9.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Blood
; 128(25): 2899-2908, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27802969
10.
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Br J Haematol
; 179(3): 430-438, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28832957
11.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
N Engl J Med
; 371(3): 213-23, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881631
12.
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Blood
; 125(19): 2915-22, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25755291
13.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Haematologica
; 102(10): 1796-1805, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751558
14.
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Lancet Oncol
; 17(10): 1409-1418, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27637985
15.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
N Engl J Med
; 369(6): 507-16, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782157
16.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 369(1): 32-42, 2013 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782158
17.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Blood
; 123(12): 1810-7, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415539
18.
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Ann Hematol
; 94(2): 249-56, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25178517
19.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Lancet Oncol
; 15(1): 48-58, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24332241
20.
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Ann N Y Acad Sci
; 1358: 82-94, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26348626